Phoenixin

What is Phoenixin?

Phoenixin (PNX) is a recently discovered endogenous neuropeptide identified in 2013 by Gina L.C. Yosten, Run-Mei Lyu, Aaron J.W. Hsueh, Orna Avsian-Kretchmer, Joshua Chang, Christopher Tullock, Sue Y. Dun, Nae J. Dun, and Willis K. Samson at Saint Louis University and Stanford, working from a bioinformatic prediction that the small integral membrane protein 20 (SMIM20) gene encoded a previously unrecognized signaling peptide. The mature peptide exists in two physiologically active forms: phoenixin-14 (PNX-14, the more abundant and more biologically active form) and phoenixin-20 (PNX-20, with a 6-residue N-terminal extension), both processed from the same SMIM20-encoded precursor. The 2013 J Neuroendocrinol paper named the peptide 'phoenixin' to evoke the mythological phoenix rising — the peptide had been hidden in plain sight in a previously uncharacterized small membrane protein and emerged through bioinformatic resurrection. Phoenixin signals through the orphan G-protein-coupled receptor GPR173, identified as the candidate receptor in 2016 by two independent laboratories: Treen, Luo, and Belsham showed in Mol Endocrinol that GPR173 mediates PNX activation of immortalized GnRH and kisspeptin neurons, and Stein, Tullock, Mathews, Garcia-Galiano, Elias, Samson, and Yosten showed in Am J Physiol Regul Integr Comp Physiol that hypothalamic Gpr173 is required for PNX's reproductive-hormone effects in vivo. The dominant biology of phoenixin is reproductive: PNX is a positive regulator of the hypothalamic-pituitary-gonadal axis, stimulating kisspeptin release in the hypothalamus and amplifying GnRH-driven luteinizing hormone secretion. Beyond reproduction, phoenixin has documented anxiolytic effects (Jiang 2015 Behav Brain Res), enhances memory and protects against amyloid-beta- and scopolamine-induced cognitive impairment in mice (Jiang 2015 Brain Res), modulates cardiac function with cardioprotective effects in ischemia-reperfusion (Rocca 2018 Cell Mol Life Sci), stimulates food intake when given centrally but not peripherally (Schalla 2017 Peptides), regulates vasopressin secretion (Gasparini 2018 Am J Physiol), and modulates thirst behavior (Stein 2020 Am J Physiol). Phoenixin is not approved as a therapeutic in any jurisdiction; it is a research peptide and an emerging drug-target.

What Phoenixin Is Investigated For

Phoenixin is an endogenous-biology and emerging-drug-target topic, not a peptide consumers take. Its scientific footprint has expanded rapidly across the decade since the 2013 discovery paper by Yosten and Samson. The reproductive biology is the most established arm: phoenixin acts in the hypothalamus to amplify kisspeptin signaling and GnRH/LH secretion, with the 2016 Treen and Stein papers identifying GPR173 as the receptor and demonstrating Gpr173 dependence in vivo. Beyond reproduction, multiple groups have characterized anxiolytic effects (PNX-14 reduces anxiety-like behavior in mice — Jiang 2015 Behav Brain Res), memory enhancement (PNX-14 improves object recognition and reverses amyloid-beta- and scopolamine-induced impairment — Jiang 2015 Brain Res), cardioprotection (Rocca 2018 Cell Mol Life Sci showed PNX-14 expression in heart and cardioprotective effects in ischemia-reperfusion), feeding (central but not peripheral PNX stimulates food intake — Schalla 2017 Peptides), vasopressin regulation (Gasparini 2018), and thirst behavior (Stein 2020). The 2018 Schalla and Stengel review in Int J Mol Sci framed phoenixin as a 'pleiotropic gut-brain peptide' — the field's working summary of the diverse and rapidly expanding action profile. The honest framing is that phoenixin is one of the more interesting recent additions to the neuropeptide repertoire, with a rich preclinical literature accumulating since 2013 and an identified receptor (GPR173) that is itself an underexplored GPCR — but the clinical chapter has not yet been written, and there is no approved phoenixin product anywhere in the world.

History & Discovery

Phoenixin was discovered in 2013 by Gina L.C. Yosten, Run-Mei Lyu, Aaron J.W. Hsueh, Orna Avsian-Kretchmer, Joshua Chang, Christopher Tullock, Sue Y. Dun, Nae J. Dun, and Willis K. Samson at Saint Louis University and Stanford University. The Yosten and Samson group at Saint Louis had been collaborating with the Hsueh laboratory at Stanford on bioinformatic identification of previously unrecognized peptide hormones encoded by uncharacterized small membrane proteins. The small integral membrane protein 20 (SMIM20) gene emerged as a candidate, and processing of the SMIM20 precursor was predicted to yield two C-terminally amidated bioactive peptides — phoenixin-14 (PNX-14) and phoenixin-20 (PNX-20). The team named the molecule 'phoenixin' to evoke the mythological phoenix rising — a previously overlooked gene encoding a hidden hormone, resurrected through bioinformatic insight. The 2013 Journal of Neuroendocrinology paper reported the synthesis of PNX-14 and PNX-20, the demonstration that they stimulate GnRH and LH secretion in vitro and in vivo, and the observation that PNX knockdown in female rats produced irregular estrous cycles and reduced fertility. The reproductive biology was the field's founding observation. The receptor identification came in 2016 from two independent and converging studies. In vitro: Treen, Cordoba-Chacon, Adank, Belsham, Wolfe, Rajkovic, and Wolfe at the University of Pittsburgh and University of Toronto reported in Molecular Endocrinology that GPR173 — a previously orphan class-A G-protein-coupled receptor — was required for phoenixin-induced calcium mobilization and ERK signaling in immortalized GT1-7 GnRH neurons and Kiss-1-derived kisspeptin neurons. In vivo: Stein, Mu, Greer, and Yosten reported in the American Journal of Physiology — Regulatory, Integrative and Comparative Physiology that hypothalamic Gpr173 antisense knockdown in female rats abolished phoenixin's stimulatory effects on reproductive hormone secretion. The convergence of in vitro and in vivo evidence established GPR173 as the phoenixin receptor and provided the molecular handle for subsequent pharmacology. The action profile expanded rapidly across the decade following discovery. Jiang, Wang, Zhou, and colleagues at Shenyang Pharmaceutical University in China published two influential 2015 papers — Behavioural Brain Research on anxiolytic-like activity of PNX-14 and Brain Research on memory enhancement and protection against amyloid-beta- and scopolamine-induced cognitive impairment. The Stengel laboratory in Berlin, working with collaborators including Schalla and Friedrich, published on phoenixin and feeding behavior (2017 Peptides), framed phoenixin as a pleiotropic gut-brain peptide in 2018 (Int J Mol Sci), and most recently characterized phoenixin's role in stress as a therapeutic target candidate (2023 Front Pharmacol). The Yosten/Samson and Stein laboratories continued to publish on vasopressin (Gasparini 2018) and thirst (Haddock 2020) regulation. The Pasqualini and Rocca laboratories in Rocca's case at the University of Calabria contributed cardiovascular biology including the 2018 Cell Mol Life Sci cardioprotection paper. As of 2026, phoenixin biology is at a stage where the field has identified the receptor, characterized a diverse action profile across reproductive, anxiety, memory, cardiovascular, feeding, and water-balance domains, and consolidated several review-level frameworks (notably the Schalla and Stengel 2018 'pleiotropic gut-brain peptide' framing and the Friedrich and Stengel 2023 stress-and-therapeutic-target framing). No phoenixin or GPR173-targeted product has reached approval; the translational chapter is open.

How It Works

Phoenixin is a small protein your brain makes that was 'discovered' in 2013 — surprisingly recent for an endogenous human peptide. It was hiding inside a larger protein called SMIM20 that scientists had not realized contained a hormone. The name comes from the mythological phoenix rising, because phoenixin emerged from a previously overlooked gene. Its main job is to help orchestrate reproduction: it tells the brain's reproductive control center (the hypothalamus) to release more kisspeptin, which then drives luteinizing hormone and the rest of the hormonal cascade that controls ovulation and testosterone. But like many peptides, phoenixin moonlights — it also reduces anxiety, helps memory, protects the heart from ischemic damage, and modulates feeding, thirst, and vasopressin release. It works through a receptor called GPR173, which until phoenixin was found was an 'orphan' (no known signaling partner). No phoenixin-based drug has been approved for any use; the molecule is still in early research.

Phoenixin is encoded as part of the small integral membrane protein 20 (SMIM20) gene, which yields a precursor that is processed by proteolytic cleavage to release two bioactive forms: phoenixin-14 (PNX-14, the more abundant and biologically active form) and phoenixin-20 (PNX-20, with a 6-residue N-terminal extension). The mature peptides are amidated at the C-terminus, and the conserved C-terminal sequence is the receptor-binding pharmacophore. Tissue distribution is broad: PNX is detected in hypothalamus (particularly arcuate, paraventricular, and supraoptic nuclei), brainstem, spinal cord, heart, ovary, testis, and gut, with circulating peptide present in plasma at low concentrations. Phoenixin signals through GPR173 (also known as SREB3, super-conserved receptor expressed in brain 3), an orphan class-A G-protein-coupled receptor that was identified as the candidate phoenixin receptor in 2016 by two independent and converging lines of evidence. Treen, Luo, and Belsham showed in Molecular Endocrinology that GPR173 knockdown in immortalized GT1-7 GnRH neurons and Kiss-1-derived hypothalamic neurons abolished phoenixin-induced calcium mobilization and ERK1/2 phosphorylation. Stein, Tullock, Mathews, Garcia-Galiano, Elias, Samson, and Yosten showed in American Journal of Physiology — Regulatory, Integrative and Comparative Physiology that hypothalamic Gpr173 antisense oligonucleotide knockdown abolished phoenixin's stimulatory effects on female reproductive hormone secretion in vivo. Subsequent work has extended GPR173 dependence to phoenixin's vasopressin-modulating (Gasparini 2018) and thirst-modulating (Haddock/Almeida-Pereira/Stein/Yosten 2020) effects. GPR173 couples to Gq/11 and produces calcium and ERK signaling characteristic of class-A GPCRs. Functionally, the dominant biology is reproductive. PNX-14 acts in the hypothalamus to stimulate kisspeptin release from KNDy (kisspeptin/neurokinin B/dynorphin) neurons in the arcuate nucleus, with kisspeptin then engaging GnRH neurons and amplifying LH/FSH secretion through the hypothalamic-pituitary-gonadal axis. PNX has been characterized as a permissive signal for normal reproductive cycling rather than a primary trigger, and Pnx knockdown in female rats produces irregular estrous cycles and reduced fertility (Yosten 2013). Beyond reproduction, multiple physiological roles have been characterized in rodents. Anxiolytic: central PNX-14 administration reduces anxiety-like behavior in mice in elevated plus maze and other paradigms (Jiang, Wang, Zhou and colleagues, Behav Brain Res 2015). Pro-cognitive and neuroprotective: PNX-14 enhances object-recognition memory and reverses amyloid-beta-1-42- and scopolamine-induced cognitive impairment in mice (Jiang 2015 Brain Res). Cardiovascular: PNX-14 is expressed in cardiac tissue, has cardioprotective effects in ischemia-reperfusion injury models, and modulates contractility (Rocca, Scavello, Granieri and colleagues, Cell Mol Life Sci 2018). Feeding: intracerebroventricular but not intraperitoneal phoenixin stimulates food intake in rats (Schalla, Prinz, Friedrich and colleagues, Peptides 2017), suggesting central appetite-modulating effects without a peripheral satiety axis. Vasopressin: phoenixin modulates vasopressin secretion through hypothalamic Gpr173 signaling (Gasparini, Stein, Loewen and colleagues, Am J Physiol Regul Integr Comp Physiol 2018). Thirst: phoenixin modulates thirst behavior through similar Gpr173-dependent hypothalamic signaling (Haddock, Almeida-Pereira, Stein, and Yosten, Am J Physiol 2020). The pleiotropic action profile and the rapid expansion of phoenixin biology since 2013 have been summarized in several reviews — McIlwraith and Belsham 2018 (Acta Pharmacol Sin), Stein, Haddock, and Samson 2018 (Peptides), Schalla and Stengel 2018 (Int J Mol Sci, 'Phoenixin: A Pleiotropic Gut-Brain Peptide'), and most recently Friedrich and Stengel 2023 (Front Pharmacol) — which together capture the field's working understanding and identify the principal open questions: receptor identity refinement, the relative importance of central versus peripheral phoenixin, and the translational potential of GPR173-targeted pharmacology. Recent 2026 work has substantially expanded the translational picture. Zhang and colleagues (Acta Pharmacol Sin 2026) reported the first therapeutic gene-therapy proof-of-concept targeting GPR173: a CaMKII-driven AAV-GPR173 construct reduced seizure frequency in mouse models of chronic and drug-resistant temporal lobe epilepsy through a mechanism involving enhanced synaptic GABA(A) receptor expression, with 25-29% of animals seizure-free on monotherapy and 83% when the vector was combined with standard antiseizure drugs. This is the first phoenixin/GPR173-pathway intervention with clear preclinical efficacy in a chronic neurological disease, and it materially shifts the framing of GPR173 from 'underexplored orphan receptor' to a receptor with a validated therapeutic axis. Additional 2026 findings extend the action profile still further: Luo and colleagues (Neuropeptides 2026) reported that the phoenixin-14/GPR173 axis promotes post-stroke angiogenesis in intracerebral-hemorrhage models through ETS1-mediated VEGF signaling — a cerebrovascular-regenerative role that complements the earlier cardioprotection literature. Li and colleagues (Behav Pharmacol 2026) reported sex-dependent analgesic effects of PNX-14 on mechanical allodynia in mouse neuropathic- and inflammatory-pain models, with efficacy in females that was estrogen-promoted and androgen-suppressed. Fiedorowicz and colleagues (BBRC 2026) reported that phoenixin regulates proliferation and UCP1 expression in rat brown preadipocytes, adding a brown-adipogenesis/thermogenesis role to the metabolic biology. Çeçen Dönmez and colleagues (Biomarkers 2026) reported the first oncology biomarker study for both PNX-14 and PNX-20 in endometrial cancer — the beginning of a clinical biomarker chapter that had been largely observational up to this point.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Phoenixin:

• 01Whether GPR173 is the only phoenixin receptor or whether additional receptors contribute to the broader pleiotropic action profile — convergent 2016 evidence supports GPR173 but receptor refinement is incomplete.
• 02Whether phoenixin or GPR173 modulators will translate into approved therapeutics for any indication — the 2026 Zhang AAV-GPR173 gene-therapy proof-of-concept in refractory temporal lobe epilepsy is the strongest translational anchor to date, but no phoenixin or GPR173-targeted product has yet entered formal human clinical development.
• 03The relative importance of central versus peripheral phoenixin — the peptide is detected in heart, gut, and reproductive tissues, but most documented effects require central administration.
• 04The structural pharmacology of GPR173 — limited cryo-EM or crystallographic data exist for the receptor, constraining structure-based drug design.
• 05Whether human plasma phoenixin levels carry diagnostic or prognostic utility in reproductive disorders, stress conditions, or metabolic disease — observational data are emerging but small.
• 06The functional difference between PNX-14 (the dominant active form) and PNX-20 — both are reported as bioactive but their relative contributions and any distinct downstream effects are not fully resolved.

Forms & Administration

Phoenixin is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic PNX-14 (and less commonly PNX-20) for in vitro receptor and signaling assays, ex vivo tissue pharmacology, and intracerebroventricular, intraperitoneal, or intravenous administration in animal models. Compounded phoenixin from peptide-marketplace channels has no validated clinical use, no quality-controlled reference product, and no characterized human dosing or safety profile.

Common Questions

Who Phoenixin Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for phoenixin because no phoenixin product has been clinically developed. Theoretical interactions follow from documented signaling. Reproductive-axis effects could interact with GnRH agonists/antagonists (leuprolide, degarelix), oral contraceptives, hormone-replacement therapy, and fertility medications. Anxiolytic effects could in principle interact with benzodiazepines, SSRIs, SNRIs. Vasopressin-modulating effects could interact with desmopressin and vasopressin receptor antagonists (tolvaptan, conivaptan). Cardiovascular effects could interact with antihypertensives and inotropes. Central feeding stimulation could interact with appetite-regulating medications including GLP-1 agonists. None of these interactions has been characterized in controlled human studies; they are mechanistic possibilities that argue against casual exogenous phoenixin exposure rather than documented clinical events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions